Healthcare provider profile · identity verified

Gilbert Emile Faustina, MD

General Surgery · WEST COVINA, CA · NPI 1558303271

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	179	43
Metformin Hcl	Metformin Hcl	109	23
Gabapentin	Gabapentin	93	38
Diflorasone Diacetate	Diflorasone Diacetate	91	21
Tamsulosin Hcl	Tamsulosin Hcl	90	19
Omeprazole	Omeprazole	86	19
Amlodipine Besylate	Amlodipine Besylate	68	24
Furosemide	Furosemide	68	18
Omeprazole-Sodium Bicarbonate	Omeprazole/Sodium Bicarbonate	67	12
Lisinopril	Lisinopril	62	19
Losartan Potassium	Losartan Potassium	54	21
Quetiapine Fumarate	Quetiapine Fumarate	52	16
Tavaborole	Tavaborole	50	suppressed
Levothyroxine Sodium	Levothyroxine Sodium	47	17
Albuterol Sulfate Hfa	Albuterol Sulfate	44	11
Trazodone Hcl	Trazodone Hcl	43	15
Metoprolol Succinate	Metoprolol Succinate	39	13
Jardiance	Empagliflozin	36	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	34	suppressed
Donepezil Hcl	Donepezil Hcl	32	11
Diclofenac Sodium	Diclofenac Sodium	30	12
Tramadol Hcl	Tramadol Hcl	30	13
Alcohol Prep Pads	Alcohol Antiseptic Pads	29	suppressed
Divalproex Sodium	Divalproex Sodium	27	suppressed
Dutasteride	Dutasteride	26	suppressed
Mirtazapine	Mirtazapine	26	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	24	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	23	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	23	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	22	suppressed
Ibuprofen	Ibuprofen	22	suppressed
Meloxicam	Meloxicam	22	suppressed
Alendronate Sodium	Alendronate Sodium	21	suppressed
Famotidine	Famotidine	21	11
Levetiracetam	Levetiracetam	21	suppressed
Humalog Kwikpen U-100	Insulin Lispro	20	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	19	suppressed
Januvia	Sitagliptin Phosphate	19	suppressed
Benazepril Hcl	Benazepril Hcl	18	suppressed
Bupropion Xl	Bupropion Hcl	18	suppressed
Fluticasone Propionate	Fluticasone Propionate	18	suppressed
Latanoprost	Latanoprost	18	suppressed
Meclizine Hcl	Meclizine Hcl	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	18	suppressed
Diclofenac Potassium	Diclofenac Potassium	17	suppressed
Sertraline Hcl	Sertraline Hcl	16	suppressed
Trulicity	Dulaglutide	16	suppressed
Ventolin Hfa	Albuterol Sulfate	16	suppressed
Chlorzoxazone	Chlorzoxazone	15	suppressed
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Glipizide	Glipizide	15	suppressed
Aripiprazole	Aripiprazole	14	suppressed
Carvedilol	Carvedilol	14	suppressed
Dihydroergotamine Mesylate	Dihydroergotamine Mesylate	13	suppressed
Divalproex Sodium Er	Divalproex Sodium	13	suppressed
Potassium Chloride	Potassium Chloride	13	suppressed
Simvastatin	Simvastatin	13	suppressed
Baclofen	Baclofen	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Farxiga	Dapagliflozin Propanediol	12	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	12	suppressed
Mounjaro	Tirzepatide	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Ozempic	Semaglutide	12	suppressed
Paliperidone Er	Paliperidone	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	12	suppressed
Cyclosporine	Cyclosporine	11	suppressed
Duloxetine Hcl	Duloxetine Hcl	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Lactulose	Lactulose	11	suppressed
Lorazepam	Lorazepam	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Tresiba Flextouch U-100	Insulin Degludec	11	suppressed
Vascepa	Icosapent Ethyl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error